Appendix 4C - Q4 FY21 Quarterly Cash Flow Report
- Written by PR Newswire
 |
Highlights:
- Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial
- Publication in Movement Disorders demonstrates that ATH434 reduces α–synuclein related neurodegeneration in MSA animal model
- Presents to MST Access Australian Micro & Small Caps Conference
- Cash balance at 30 June 2021 of A$28M
MELBOURNE,...
